AVITA Medical, Inc. (RCEL) has a consensus analyst rating of Buy, based on 7 analysts covering the stock. Of those, 4 recommend buying, 3 recommend holding, and 0 recommend selling.
The analyst consensus price target for RCEL is $3.50, representing a -32.2% downside from the current price of $5.16. Price targets range from a low of $3.50 to a high of $3.50.
